Browse studies

Find your next paid study

22 recruiting studies matching your filters

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post…

Leukemia/LymphomaCutaneous T Cell LymphomaATLL

Estimated

~$10 – $1,050

Kyowa Kirin, Inc.NCT04014374

Phase 1

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the trea…

Cutaneous T Cell Lymphoma

Estimated

~$10 – $6,250

Northwestern UniversityNCT05728879

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microb…

Cutaneous T Cell Lymphoma

Estimated

~$10 – $750

Northwestern UniversityNCT03932279

Phase 2

Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have …

T-cell LymphomaGraft Versus Host DiseaseLymphoma, T-Cell+5 more

Estimated

~$10 – $7,500

Jonathan BrammerNCT07356245

Phase 2

THERAKOS® CELLEX Photopheresis System as an Interventional Therapy for the Treatment of Early Stage CTCL (Mycosis Fungoides), an Open-label, Single-arm, Multi-center, Phase II Study

The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CT…

Cutaneous T Cell LymphomaMycosis Fungoides

Estimated

~$10 – $6,250

Columbia UniversityNCT05680558

Phase 1

A Phase I/IB Study of Ropeginterferon in Patients With Cutaneous T-Cell Lymphoma (CTCL)

This is a single-center, phase I/IB study to identify the recommended phase II dose of Ropeginterferon-alfa 2b (P1101) in patients with CTCL who have failed at…

Cutaneous T Cell Lymphoma

Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT07047885

Phase 3

A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte™ (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

CTCL/ Mycosis FungoidesCTCLMycosis Fungoides+1 more

A Phase II Study of Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractor…

Cutaneous T Cell LymphomaFungoides Mycosis Sezary Syndrome

Estimated

~$10 – $6,250

University of Michigan Rogel Cancer CenterNCT05956041

Phase 1

Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)

This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the stu…

Cutaneous T Cell LymphomaMycosis Fungoides

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT05414500

Phase 2

Phase II Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patien…

T Cell LymphomaT-cell Lymphoma

Estimated

~$10 – $6,250

Yale UniversityNCT05996185